<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1991-08-01" modified="2018-01-31" version="216">
<accession>P22681</accession>
<accession>A3KMP8</accession>
<name>CBL_HUMAN</name>
<protein>
<recommendedName>
<fullName>E3 ubiquitin-protein ligase CBL</fullName>
<ecNumber evidence="23 33 39">2.3.2.27</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Casitas B-lineage lymphoma proto-oncogene</fullName>
</alternativeName>
<alternativeName>
<fullName>Proto-oncogene c-Cbl</fullName>
</alternativeName>
<alternativeName>
<fullName>RING finger protein 55</fullName>
</alternativeName>
<alternativeName>
<fullName evidence="57">RING-type E3 ubiquitin transferase CBL</fullName>
</alternativeName>
<alternativeName>
<fullName>Signal transduction protein CBL</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">CBL</name>
<name type="synonym">CBL2</name>
<name type="synonym">RNF55</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="Oncogene" volume="6" first="653" last="657">
<title>The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.</title>
<authorList>
<person name="Blake T.J."/>
<person name="Shapiro M."/>
<person name="Morse H.C. III"/>
<person name="Langdon W.Y."/>
</authorList>
<dbReference type="PubMed" id="2030914"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2006" name="Nature" volume="440" first="497" last="500">
<title>Human chromosome 11 DNA sequence and analysis including novel gene identification.</title>
<authorList>
<person name="Taylor T.D."/>
<person name="Noguchi H."/>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Kuroki Y."/>
<person name="Dewar K."/>
<person name="Lloyd C."/>
<person name="Itoh T."/>
<person name="Takeda T."/>
<person name="Kim D.-W."/>
<person name="She X."/>
<person name="Barlow K.F."/>
<person name="Bloom T."/>
<person name="Bruford E."/>
<person name="Chang J.L."/>
<person name="Cuomo C.A."/>
<person name="Eichler E."/>
<person name="FitzGerald M.G."/>
<person name="Jaffe D.B."/>
<person name="LaButti K."/>
<person name="Nicol R."/>
<person name="Park H.-S."/>
<person name="Seaman C."/>
<person name="Sougnez C."/>
<person name="Yang X."/>
<person name="Zimmer A.R."/>
<person name="Zody M.C."/>
<person name="Birren B.W."/>
<person name="Nusbaum C."/>
<person name="Fujiyama A."/>
<person name="Hattori M."/>
<person name="Rogers J."/>
<person name="Lander E.S."/>
<person name="Sakaki Y."/>
</authorList>
<dbReference type="PubMed" id="16554811"/>
<dbReference type="DOI" id="10.1038/nature04632"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1999" name="Biochem. Biophys. Res. Commun." volume="257" first="129" last="138">
<title>The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-tyrosine kinase.</title>
<authorList>
<person name="Howlett C.J."/>
<person name="Bisson S.A."/>
<person name="Resek M.E."/>
<person name="Tigley A.W."/>
<person name="Robbins S.M."/>
</authorList>
<dbReference type="PubMed" id="10092522"/>
<dbReference type="DOI" id="10.1006/bbrc.1999.0427"/>
</citation>
<scope>PHOSPHORYLATION BY HCK</scope>
<scope>INTERACTION WITH HCK</scope>
</reference>
<reference key="5">
<citation type="journal article" date="1999" name="Science" volume="286" first="309" last="312">
<title>The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.</title>
<authorList>
<person name="Joazeiro C.A."/>
<person name="Wing S.S."/>
<person name="Huang H.-K."/>
<person name="Leverson J.D."/>
<person name="Hunter T."/>
<person name="Liu Y.-C."/>
</authorList>
<dbReference type="PubMed" id="10514377"/>
<dbReference type="DOI" id="10.1126/science.286.5438.309"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="6">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="22921" last="22924">
<title>The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor.</title>
<authorList>
<person name="Donovan J.A."/>
<person name="Wange R.L."/>
<person name="Langdon W.Y."/>
<person name="Samelson L.E."/>
</authorList>
<dbReference type="PubMed" id="8083187"/>
</citation>
<scope>INTERACTION WITH BLK</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="20242" last="20245">
<title>Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.</title>
<authorList>
<person name="Galisteo M.L."/>
<person name="Dikic I."/>
<person name="Batzer A.G."/>
<person name="Langdon W.Y."/>
<person name="Schlessinger J."/>
</authorList>
<dbReference type="PubMed" id="7657591"/>
<dbReference type="DOI" id="10.1074/jbc.270.35.20242"/>
</citation>
<scope>PHOSPHORYLATION BY EGFR</scope>
<scope>INTERACTION WITH EGFR</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="33140" last="33144">
<title>The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70.</title>
<authorList>
<person name="Lupher M.L. Jr."/>
<person name="Songyang Z."/>
<person name="Shoelson S.E."/>
<person name="Cantley L.C."/>
<person name="Band H."/>
</authorList>
<dbReference type="PubMed" id="9407100"/>
<dbReference type="DOI" id="10.1074/jbc.272.52.33140"/>
</citation>
<scope>INTERACTION WITH ZAP70</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="8867" last="8874">
<title>Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases.</title>
<authorList>
<person name="Deckert M."/>
<person name="Elly C."/>
<person name="Altman A."/>
<person name="Liu Y.C."/>
</authorList>
<dbReference type="PubMed" id="9535867"/>
<dbReference type="DOI" id="10.1074/jbc.273.15.8867"/>
</citation>
<scope>PHOSPHORYLATION BY SYK AND FYN</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2002" name="J. Exp. Med." volume="196" first="1617" last="1626">
<title>Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling.</title>
<authorList>
<person name="Brdicka T."/>
<person name="Imrich M."/>
<person name="Angelisova P."/>
<person name="Brdickova N."/>
<person name="Horvath O."/>
<person name="Spicka J."/>
<person name="Hilgert I."/>
<person name="Luskova P."/>
<person name="Draber P."/>
<person name="Novak P."/>
<person name="Engels N."/>
<person name="Wienands J."/>
<person name="Simeoni L."/>
<person name="Oesterreicher J."/>
<person name="Aguado E."/>
<person name="Malissen M."/>
<person name="Schraven B."/>
<person name="Horejsi V."/>
</authorList>
<dbReference type="PubMed" id="12486104"/>
<dbReference type="DOI" id="10.1084/jem.20021405"/>
</citation>
<scope>INTERACTION WITH LAT2</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2002" name="Oncogene" volume="21" first="1079" last="1089">
<title>C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus.</title>
<authorList>
<person name="Wilhelmsen K."/>
<person name="Burkhalter S."/>
<person name="van der Geer P."/>
</authorList>
<dbReference type="PubMed" id="11850825"/>
<dbReference type="DOI" id="10.1038/sj.onc.1205166"/>
</citation>
<scope>INTERACTION WITH CSF1R</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2002" name="Oncogene" volume="21" first="1707" last="1716">
<title>Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation.</title>
<authorList>
<person name="Howlett C.J."/>
<person name="Robbins S.M."/>
</authorList>
<dbReference type="PubMed" id="11896602"/>
<dbReference type="DOI" id="10.1038/sj.onc.1205228"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>UBIQUITINATION</scope>
<scope>MUTAGENESIS OF CYS-381</scope>
<scope>INTERACTION WITH HCK</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2003" name="Biochem. J." volume="370" first="687" last="694">
<title>Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils.</title>
<authorList>
<person name="Melander F."/>
<person name="Andersson T."/>
<person name="Dib K."/>
</authorList>
<dbReference type="PubMed" id="12435267"/>
<dbReference type="DOI" id="10.1042/BJ20021201"/>
</citation>
<scope>INTERACTION WITH FGR</scope>
<scope>PHOSPHORYLATION BY FGR</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1999" name="Leukemia" volume="13" first="760" last="767">
<title>APS, an adaptor protein containing pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl.</title>
<authorList>
<person name="Wakioka T."/>
<person name="Sasaki A."/>
<person name="Mitsui K."/>
<person name="Yokouchi M."/>
<person name="Inoue A."/>
<person name="Komiya S."/>
<person name="Yoshimura A."/>
</authorList>
<dbReference type="PubMed" id="10374881"/>
<dbReference type="DOI" id="10.1038/sj/leu/2401397"/>
</citation>
<scope>INTERACTION WITH SH2B2</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1999" name="Oncogene" volume="18" first="759" last="767">
<title>APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.</title>
<authorList>
<person name="Yokouchi M."/>
<person name="Wakioka T."/>
<person name="Sakamoto H."/>
<person name="Yasukawa H."/>
<person name="Ohtsuka S."/>
<person name="Sasaki A."/>
<person name="Ohtsubo M."/>
<person name="Valius M."/>
<person name="Inoue A."/>
<person name="Komiya S."/>
<person name="Yoshimura A."/>
</authorList>
<dbReference type="PubMed" id="9989826"/>
<dbReference type="DOI" id="10.1038/sj.onc.1202326"/>
</citation>
<scope>INTERACTION WITH SH2B2</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1999" name="Proc. Natl. Acad. Sci. U.S.A." volume="96" first="9775" last="9780">
<title>SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling.</title>
<authorList>
<person name="Tang J."/>
<person name="Sawasdikosol S."/>
<person name="Chang J.-H."/>
<person name="Burakoff S.J."/>
</authorList>
<dbReference type="PubMed" id="10449770"/>
<dbReference type="DOI" id="10.1073/pnas.96.17.9775"/>
</citation>
<scope>INTERACTION WITH SLA AND ZAP70</scope>
<scope>MUTAGENESIS OF GLY-306</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2001" name="J. Exp. Med." volume="194" first="1263" last="1276">
<title>Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling.</title>
<authorList>
<person name="Holland S.J."/>
<person name="Liao X.C."/>
<person name="Mendenhall M.K."/>
<person name="Zhou X."/>
<person name="Pardo J."/>
<person name="Chu P."/>
<person name="Spencer C."/>
<person name="Fu A.C."/>
<person name="Sheng N."/>
<person name="Yu P."/>
<person name="Pali E."/>
<person name="Nagin A."/>
<person name="Shen M."/>
<person name="Yu S."/>
<person name="Chan E."/>
<person name="Wu X."/>
<person name="Li C."/>
<person name="Woisetschlager M."/>
<person name="Aversa G."/>
<person name="Kolbinger F."/>
<person name="Bennett M.K."/>
<person name="Molineaux S."/>
<person name="Luo Y."/>
<person name="Payan D.G."/>
<person name="Mancebo H.S.Y."/>
<person name="Wu J."/>
</authorList>
<dbReference type="PubMed" id="11696592"/>
<dbReference type="DOI" id="10.1084/jem.194.9.1263"/>
</citation>
<scope>INTERACTION WITH SLA2</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2001" name="J. Biol. Chem." volume="276" first="4957" last="4963">
<title>The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction.</title>
<authorList>
<person name="Kirsch K.H."/>
<person name="Georgescu M.M."/>
<person name="Shishido T."/>
<person name="Langdon W.Y."/>
<person name="Birge R.B."/>
<person name="Hanafusa H."/>
</authorList>
<dbReference type="PubMed" id="11067845"/>
<dbReference type="DOI" id="10.1074/jbc.M005784200"/>
</citation>
<scope>INTERACTION WITH CD2AP</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2002" name="Mol. Cell. Biol." volume="22" first="3599" last="3609">
<title>APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes.</title>
<authorList>
<person name="Liu J."/>
<person name="Kimura A."/>
<person name="Baumann C.A."/>
<person name="Saltiel A.R."/>
</authorList>
<dbReference type="PubMed" id="11997497"/>
<dbReference type="DOI" id="10.1128/MCB.22.11.3599-3609.2002"/>
</citation>
<scope>INTERACTION WITH SH2B2</scope>
<scope>MUTAGENESIS OF TYR-371; TYR-700; TYR-731 AND TYR-774</scope>
<scope>PHOSPHORYLATION AT TYR-371; TYR-700 AND TYR-774</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2003" name="Biochem. Biophys. Res. Commun." volume="300" first="494" last="500">
<title>The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2.</title>
<authorList>
<person name="Vandenbroere I."/>
<person name="Paternotte N."/>
<person name="Dumont J.E."/>
<person name="Erneux C."/>
<person name="Pirson I."/>
</authorList>
<dbReference type="PubMed" id="12504111"/>
<dbReference type="DOI" id="10.1016/S0006-291X(02)02894-2"/>
</citation>
<scope>INTERACTION WITH INPPL1</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2003" name="Proc. Natl. Acad. Sci. U.S.A." volume="100" first="443" last="448">
<title>Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.</title>
<authorList>
<person name="Salomon A.R."/>
<person name="Ficarro S.B."/>
<person name="Brill L.M."/>
<person name="Brinker A."/>
<person name="Phung Q.T."/>
<person name="Ericson C."/>
<person name="Sauer K."/>
<person name="Brock A."/>
<person name="Horn D.M."/>
<person name="Schultz P.G."/>
<person name="Peters E.C."/>
</authorList>
<dbReference type="PubMed" id="12522270"/>
<dbReference type="DOI" id="10.1073/pnas.2436191100"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2004" name="Anal. Chem." volume="76" first="2763" last="2772">
<title>Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.</title>
<authorList>
<person name="Brill L.M."/>
<person name="Salomon A.R."/>
<person name="Ficarro S.B."/>
<person name="Mukherji M."/>
<person name="Stettler-Gill M."/>
<person name="Peters E.C."/>
</authorList>
<dbReference type="PubMed" id="15144186"/>
<dbReference type="DOI" id="10.1021/ac035352d"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="23">
<citation type="journal article" date="2004" name="Oncogene" volume="23" first="1645" last="1655">
<title>Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation.</title>
<authorList>
<person name="Kim M."/>
<person name="Tezuka T."/>
<person name="Tanaka K."/>
<person name="Yamamoto T."/>
</authorList>
<dbReference type="PubMed" id="14661060"/>
<dbReference type="DOI" id="10.1038/sj.onc.1207298"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2004" name="Cell. Mol. Life Sci." volume="61" first="2535" last="2548">
<title>Signal transduction via the stem cell factor receptor/c-Kit.</title>
<authorList>
<person name="Ronnstrand L."/>
</authorList>
<dbReference type="PubMed" id="15526160"/>
<dbReference type="DOI" id="10.1007/s00018-004-4189-6"/>
</citation>
<scope>REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2004" name="FEBS Lett." volume="577" first="555" last="562">
<title>Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.</title>
<authorList>
<person name="Grossmann A.H."/>
<person name="Kolibaba K.S."/>
<person name="Willis S.G."/>
<person name="Corbin A.S."/>
<person name="Langdon W.S."/>
<person name="Deininger M.W."/>
<person name="Druker B.J."/>
</authorList>
<dbReference type="PubMed" id="15556646"/>
<dbReference type="DOI" id="10.1016/j.febslet.2004.10.054"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-700</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="17660" last="17666">
<title>Src kinase activity is essential for osteoclast function.</title>
<authorList>
<person name="Miyazaki T."/>
<person name="Sanjay A."/>
<person name="Neff L."/>
<person name="Tanaka S."/>
<person name="Horne W.C."/>
<person name="Baron R."/>
</authorList>
<dbReference type="PubMed" id="14739300"/>
<dbReference type="DOI" id="10.1074/jbc.M311032200"/>
</citation>
<scope>FUNCTION</scope>
<scope>PHOSPHORYLATION AT TYR-731</scope>
<scope>MUTAGENESIS OF TYR-731</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="36259" last="36267">
<title>Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.</title>
<authorList>
<person name="Kaabeche K."/>
<person name="Lemonnier J."/>
<person name="Le Mee S."/>
<person name="Caverzasio J."/>
<person name="Marie P.J."/>
</authorList>
<dbReference type="PubMed" id="15190072"/>
<dbReference type="DOI" id="10.1074/jbc.M402469200"/>
</citation>
<scope>FUNCTION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INTERACTION WITH FGFR2; LYN AND FYN</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2004" name="J. Cell Sci." volume="117" first="3319" last="3329">
<title>ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.</title>
<authorList>
<person name="Motegi A."/>
<person name="Fujimoto J."/>
<person name="Kotani M."/>
<person name="Sakuraba H."/>
<person name="Yamamoto T."/>
</authorList>
<dbReference type="PubMed" id="15226403"/>
<dbReference type="DOI" id="10.1242/jcs.01183"/>
</citation>
<scope>INTERACTION WITH ALK</scope>
<scope>PHOSPHORYLATION BY ALK</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2005" name="Biochem. Biophys. Res. Commun." volume="333" first="180" last="185">
<title>Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation.</title>
<authorList>
<person name="Valverde P."/>
</authorList>
<dbReference type="PubMed" id="15958209"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2005.05.086"/>
</citation>
<scope>INTERACTION WITH AXL</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2005" name="Biochem. Biophys. Res. Commun." volume="337" first="1" last="13">
<title>Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.</title>
<authorList>
<person name="Roskoski R. Jr."/>
</authorList>
<dbReference type="PubMed" id="16129412"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2005.08.055"/>
</citation>
<scope>REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2005" name="Nat. Biotechnol." volume="23" first="94" last="101">
<title>Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.</title>
<authorList>
<person name="Rush J."/>
<person name="Moritz A."/>
<person name="Lee K.A."/>
<person name="Guo A."/>
<person name="Goss V.L."/>
<person name="Spek E.J."/>
<person name="Zhang H."/>
<person name="Zha X.-M."/>
<person name="Polakiewicz R.D."/>
<person name="Comb M.J."/>
</authorList>
<dbReference type="PubMed" id="15592455"/>
<dbReference type="DOI" id="10.1038/nbt1046"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2006" name="Nat. Biotechnol." volume="24" first="1285" last="1292">
<title>A probability-based approach for high-throughput protein phosphorylation analysis and site localization.</title>
<authorList>
<person name="Beausoleil S.A."/>
<person name="Villen J."/>
<person name="Gerber S.A."/>
<person name="Rush J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="16964243"/>
<dbReference type="DOI" id="10.1038/nbt1240"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-900</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="33">
<citation type="journal article" date="2007" name="FEBS J." volume="274" first="3078" last="3093">
<title>The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.</title>
<authorList>
<person name="Bonaventure J."/>
<person name="Horne W.C."/>
<person name="Baron R."/>
</authorList>
<dbReference type="PubMed" id="17509076"/>
<dbReference type="DOI" id="10.1111/j.1742-4658.2007.05835.x"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="29336" last="29347">
<title>Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation.</title>
<authorList>
<person name="Reddi A.L."/>
<person name="Ying G."/>
<person name="Duan L."/>
<person name="Chen G."/>
<person name="Dimri M."/>
<person name="Douillard P."/>
<person name="Druker B.J."/>
<person name="Naramura M."/>
<person name="Band V."/>
<person name="Band H."/>
</authorList>
<dbReference type="PubMed" id="17620338"/>
<dbReference type="DOI" id="10.1074/jbc.M701797200"/>
</citation>
<scope>INTERACTION WITH PDGFRB</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2008" name="Blood" volume="111" first="3821" last="3829">
<title>Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.</title>
<authorList>
<person name="Wu J."/>
<person name="Meng F."/>
<person name="Lu H."/>
<person name="Kong L."/>
<person name="Bornmann W."/>
<person name="Peng Z."/>
<person name="Talpaz M."/>
<person name="Donato N.J."/>
</authorList>
<dbReference type="PubMed" id="18235045"/>
<dbReference type="DOI" id="10.1182/blood-2007-08-109330"/>
</citation>
<scope>INTERACTION WITH LYN</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2008" name="Bone" volume="42" first="1032" last="1039">
<title>FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival.</title>
<authorList>
<person name="Dufour C."/>
<person name="Guenou H."/>
<person name="Kaabeche K."/>
<person name="Bouvard D."/>
<person name="Sanjay A."/>
<person name="Marie P.J."/>
</authorList>
<dbReference type="PubMed" id="18374639"/>
<dbReference type="DOI" id="10.1016/j.bone.2008.02.009"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH FGFR2</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="38">
<citation type="journal article" date="2008" name="Traffic" volume="9" first="251" last="266">
<title>Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway.</title>
<authorList>
<person name="Fasen K."/>
<person name="Cerretti D.P."/>
<person name="Huynh-Do U."/>
</authorList>
<dbReference type="PubMed" id="18034775"/>
<dbReference type="DOI" id="10.1111/j.1600-0854.2007.00679.x"/>
</citation>
<scope>INTERACTION WITH EPHB1</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2009" name="Biochem. J." volume="423" first="375" last="380">
<title>Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation.</title>
<authorList>
<person name="Wehrle C."/>
<person name="Van Slyke P."/>
<person name="Dumont D.J."/>
</authorList>
<dbReference type="PubMed" id="19689429"/>
<dbReference type="DOI" id="10.1042/BJ20091010"/>
</citation>
<scope>INTERACTION WITH TEK/TIE2</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2009" name="Curr. Biol." volume="19" first="1788" last="1798">
<title>An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.</title>
<authorList>
<person name="Tarcic G."/>
<person name="Boguslavsky S.K."/>
<person name="Wakim J."/>
<person name="Kiuchi T."/>
<person name="Liu A."/>
<person name="Reinitz F."/>
<person name="Nathanson D."/>
<person name="Takahashi T."/>
<person name="Mischel P.S."/>
<person name="Ng T."/>
<person name="Yarden Y."/>
</authorList>
<dbReference type="PubMed" id="19836242"/>
<dbReference type="DOI" id="10.1016/j.cub.2009.09.048"/>
</citation>
<scope>INTERACTION WITH EGFR</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="42">
<citation type="journal article" date="2010" name="Cell. Signal." volume="22" first="1363" last="1368">
<title>Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration.</title>
<authorList>
<person name="Wardega P."/>
<person name="Heldin C.H."/>
<person name="Lennartsson J."/>
</authorList>
<dbReference type="PubMed" id="20494825"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2010.05.004"/>
</citation>
<scope>INTERACTION WITH PDGFRB</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="44">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="24443" last="24450">
<title>The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.</title>
<authorList>
<person name="Severe N."/>
<person name="Miraoui H."/>
<person name="Marie P.J."/>
</authorList>
<dbReference type="PubMed" id="21596750"/>
<dbReference type="DOI" id="10.1074/jbc.M110.197525"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH FGFR2</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439; SER-483 AND SER-669</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="47">
<citation type="journal article" date="2014" name="Hum. Mutat." volume="35" first="1372" last="1381">
<title>RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.</title>
<authorList>
<person name="Brand K."/>
<person name="Kentsch H."/>
<person name="Glashoff C."/>
<person name="Rosenberger G."/>
</authorList>
<dbReference type="PubMed" id="25178484"/>
<dbReference type="DOI" id="10.1002/humu.22682"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS NSLL GLU-382; TYR-390 AND GLN-420</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2010" name="Nat. Rev. Cancer" volume="10" first="116" last="129">
<title>Fibroblast growth factor signalling: from development to cancer.</title>
<authorList>
<person name="Turner N."/>
<person name="Grose R."/>
</authorList>
<dbReference type="PubMed" id="20094046"/>
<dbReference type="DOI" id="10.1038/nrc2780"/>
</citation>
<scope>REVIEW ON FUNCTION IN FGF SIGNALING</scope>
<scope>UBIQUITINATION OF FGFR1</scope>
</reference>
<reference key="49">
<citation type="journal article" date="1999" name="Nature" volume="398" first="84" last="90">
<title>Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase.</title>
<authorList>
<person name="Meng W."/>
<person name="Sawasdikosol S."/>
<person name="Burakoff S.J."/>
<person name="Eck M.J."/>
</authorList>
<dbReference type="PubMed" id="10078535"/>
<dbReference type="DOI" id="10.1038/18050"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 47-350 IN COMPLEX WITH ZAP70 PEPTIDE AND CALCIUM IONS</scope>
<scope>CALCIUM-BINDING SITE</scope>
<scope>MUTAGENESIS OF SER-80; PRO-82; ASP-229; GLU-240; ARG-294 AND GLY-306</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2000" name="Cell" volume="102" first="533" last="539">
<title>Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.</title>
<authorList>
<person name="Zheng N."/>
<person name="Wang P."/>
<person name="Jeffrey P.D."/>
<person name="Pavletich N.P."/>
</authorList>
<dbReference type="PubMed" id="10966114"/>
<dbReference type="DOI" id="10.1016/S0092-8674(00)00057-X"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 47-434 IN COMPLEX WITH ZAP70 AND UBE2L3</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2010" name="Am. J. Hum. Genet." volume="87" first="250" last="257">
<title>Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.</title>
<authorList>
<person name="Martinelli S."/>
<person name="De Luca A."/>
<person name="Stellacci E."/>
<person name="Rossi C."/>
<person name="Checquolo S."/>
<person name="Lepri F."/>
<person name="Caputo V."/>
<person name="Silvano M."/>
<person name="Buscherini F."/>
<person name="Consoli F."/>
<person name="Ferrara G."/>
<person name="Digilio M.C."/>
<person name="Cavaliere M.L."/>
<person name="van Hagen J.M."/>
<person name="Zampino G."/>
<person name="van der Burgt I."/>
<person name="Ferrero G.B."/>
<person name="Mazzanti L."/>
<person name="Screpanti I."/>
<person name="Yntema H.G."/>
<person name="Nillesen W.M."/>
<person name="Savarirayan R."/>
<person name="Zenker M."/>
<person name="Dallapiccola B."/>
<person name="Gelb B.D."/>
<person name="Tartaglia M."/>
</authorList>
<dbReference type="PubMed" id="20619386"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2010.06.015"/>
</citation>
<scope>VARIANTS NSLL PRO-367; GLU-382; TYR-390 AND GLN-420</scope>
<scope>CHARACTERIZATION OF VARIANTS NSLL TYR-390 AND GLN-420</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2010" name="J. Biol. Chem." volume="285" first="32596" last="32605">
<title>Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.</title>
<authorList>
<person name="Fernandes M.S."/>
<person name="Reddy M.M."/>
<person name="Croteau N.J."/>
<person name="Walz C."/>
<person name="Weisbach H."/>
<person name="Podar K."/>
<person name="Band H."/>
<person name="Carroll M."/>
<person name="Reiter A."/>
<person name="Larson R.A."/>
<person name="Salgia R."/>
<person name="Griffin J.D."/>
<person name="Sattler M."/>
</authorList>
<dbReference type="PubMed" id="20622007"/>
<dbReference type="DOI" id="10.1074/jbc.M110.106161"/>
</citation>
<scope>VARIANTS ARG-287; SER-LYS-365 INS; HIS-371 AND LEU-499</scope>
<scope>CHARACTERIZATION OF VARIANTS SER-LYS-365 INS AND HIS-371</scope>
<scope>PHOSPHORYLATION AT TYR-674; TYR-700 AND TYR-774</scope>
</reference>
<comment type="function">
<text evidence="23 28 33 34 35 39 43 44 50">Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3.</text>
</comment>
<comment type="catalytic activity">
<text evidence="23 33 39">S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.</text>
</comment>
<comment type="pathway">
<text>Protein modification; protein ubiquitination.</text>
</comment>
<comment type="subunit">
<text evidence="15 19 20 21 22 24 25 26 27 28 29 30 31 32 35 36 38 40 41 42 43 44 45 47 50 52 53 54 56">Interacts (phosphorylated at Tyr-731) with PIK3R1. Associates with NCK via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP via its second SH3 domain. Binds to UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May interact with CBLB (By similarity). Interacts with ALK, AXL, BLK, FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates receptor degradation through ubiquitination. Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine phosphorylated). Interacts with SH3KBP1 and this interaction is inhibited in the presence of SHKBP1 (By similarity). Interacts with SIGLEC10 (By similarity).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-7358775">
<id>Q8IZP0-2</id>
<label>ABI1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-717515">
<id>Q14155</id>
<label>ARHGEF7</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-298152">
<id>Q9Y5K6</id>
<label>CD2AP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-886">
<id>P46108</id>
<label>CRK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>8</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-910">
<id>P46109</id>
<label>CRKL</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-297353">
<id>P00533</id>
<label>EGFR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>22</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-4303189">
<id>P55085</id>
<label>F2RL1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-1026718">
<id>P17948</id>
<label>FLT1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-524514">
<id>P39688</id>
<label>Fyn</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-401755">
<id>P62993</id>
<label>GRB2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>10</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-9834454">
<id>P08631-2</id>
<label>HCK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-602041">
<id>Q15811</id>
<label>ITSN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>12</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-286483">
<id>P45983</id>
<label>MAPK8</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-1039152">
<id>P08581</id>
<label>MET</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>15</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-1028226">
<id>P04629</id>
<label>NTRK1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-346930">
<id>O00459</id>
<label>PIK3R2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-79893">
<id>Q92569</id>
<label>PIK3R3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-15628084">
<id>F1SDV6</id>
<label>PLCG1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-8013886">
<id>P08487</id>
<label>PLCG1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-7507432">
<id>O14492</id>
<label>SH2B2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-346595">
<id>Q96B97</id>
<label>SH3KBP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>18</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-742487">
<id>O43597</id>
<label>SPRY2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>17</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-354861">
<id>Q9C004</id>
<label>SPRY4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-621482">
<id>P12931</id>
<label>SRC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>8</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-78302">
<id>P43405</id>
<label>SYK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-347677">
<id>P62837</id>
<label>UBE2D2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-359815">
<id>P31946</id>
<label>YWHAB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-359854">
<id>P27348</id>
<label>YWHAQ</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-518228"/>
<interactant intactId="EBI-1211276">
<id>P43403</id>
<label>ZAP70</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location>Cell membrane</location>
</subcellularLocation>
<text>Colocalizes with FGFR2 in lipid rafts at the cell membrane.</text>
</comment>
<comment type="domain">
<text>The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.</text>
</comment>
<comment type="domain">
<text>The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.</text>
</comment>
<comment type="PTM">
<text evidence="14 20 27 29 30 34 35 36 37 39 41 47 49 52 55">Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK.</text>
</comment>
<comment type="PTM">
<text evidence="28 46">Ubiquitinated, leading to its degradation via the proteasome.</text>
</comment>
<comment type="disease" evidence="48 51">
<disease id="DI-02913">
<name>Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia</name>
<acronym>NSLL</acronym>
<description>A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.</description>
<dbReference type="MIM" id="613563"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="miscellaneous">
<text>This protein has one functional calcium-binding site.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/CBLID171.html"/>
</comment>
<dbReference type="EC" id="2.3.2.27" evidence="23 33 39"/>
<dbReference type="EMBL" id="X57110">
<property type="protein sequence ID" value="CAA40393.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AP002956">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC132733">
<property type="protein sequence ID" value="AAI32734.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC136463">
<property type="protein sequence ID" value="AAI36464.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS8418.1"/>
<dbReference type="PIR" id="A43817">
<property type="entry name" value="A43817"/>
</dbReference>
<dbReference type="RefSeq" id="NP_005179.2">
<property type="nucleotide sequence ID" value="NM_005188.3"/>
</dbReference>
<dbReference type="UniGene" id="Hs.504096"/>
<dbReference type="PDB" id="1B47">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/B/C=47-350"/>
</dbReference>
<dbReference type="PDB" id="1FBV">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A=47-434"/>
</dbReference>
<dbReference type="PDB" id="1YVH">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.05"/>
<property type="chains" value="A=25-351"/>
</dbReference>
<dbReference type="PDB" id="2CBL">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=47-351"/>
</dbReference>
<dbReference type="PDB" id="2JUJ">
<property type="method" value="NMR"/>
<property type="chains" value="A=851-906"/>
</dbReference>
<dbReference type="PDB" id="2K4D">
<property type="method" value="NMR"/>
<property type="chains" value="A=358-437"/>
</dbReference>
<dbReference type="PDB" id="2OO9">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A/B/C=856-895"/>
</dbReference>
<dbReference type="PDB" id="2Y1M">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.67"/>
<property type="chains" value="A/B/C/D/E/F=47-435"/>
</dbReference>
<dbReference type="PDB" id="2Y1N">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/C=47-435"/>
</dbReference>
<dbReference type="PDB" id="3BUM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="B=25-351"/>
</dbReference>
<dbReference type="PDB" id="3BUN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="B=25-351"/>
</dbReference>
<dbReference type="PDB" id="3BUO">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="B/D=25-351"/>
</dbReference>
<dbReference type="PDB" id="3BUW">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.45"/>
<property type="chains" value="B/D=25-351"/>
</dbReference>
<dbReference type="PDB" id="3BUX">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.35"/>
<property type="chains" value="B/D=25-351"/>
</dbReference>
<dbReference type="PDB" id="3OB1">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="B=25-351"/>
</dbReference>
<dbReference type="PDB" id="3OB2">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="B=25-351"/>
</dbReference>
<dbReference type="PDB" id="3PLF">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.92"/>
<property type="chains" value="B/D=25-351"/>
</dbReference>
<dbReference type="PDB" id="4A49">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.21"/>
<property type="chains" value="A=354-435"/>
</dbReference>
<dbReference type="PDB" id="4A4B">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.79"/>
<property type="chains" value="A=47-435"/>
</dbReference>
<dbReference type="PDB" id="4A4C">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=47-435"/>
</dbReference>
<dbReference type="PDB" id="4GPL">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="B=47-351"/>
</dbReference>
<dbReference type="PDB" id="5HKW">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="A/B/C=47-351"/>
</dbReference>
<dbReference type="PDB" id="5HKX">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=47-435"/>
</dbReference>
<dbReference type="PDB" id="5HKY">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=47-351"/>
</dbReference>
<dbReference type="PDB" id="5HKZ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=47-351"/>
</dbReference>
<dbReference type="PDB" id="5HL0">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=47-351"/>
</dbReference>
<dbReference type="PDB" id="5J3X">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.82"/>
<property type="chains" value="A/B/C/D/E/F=47-435"/>
</dbReference>
<dbReference type="PDB" id="5O76">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.47"/>
<property type="chains" value="A/C=47-435"/>
</dbReference>
<dbReference type="PDBsum" id="1B47"/>
<dbReference type="PDBsum" id="1FBV"/>
<dbReference type="PDBsum" id="1YVH"/>
<dbReference type="PDBsum" id="2CBL"/>
<dbReference type="PDBsum" id="2JUJ"/>
<dbReference type="PDBsum" id="2K4D"/>
<dbReference type="PDBsum" id="2OO9"/>
<dbReference type="PDBsum" id="2Y1M"/>
<dbReference type="PDBsum" id="2Y1N"/>
<dbReference type="PDBsum" id="3BUM"/>
<dbReference type="PDBsum" id="3BUN"/>
<dbReference type="PDBsum" id="3BUO"/>
<dbReference type="PDBsum" id="3BUW"/>
<dbReference type="PDBsum" id="3BUX"/>
<dbReference type="PDBsum" id="3OB1"/>
<dbReference type="PDBsum" id="3OB2"/>
<dbReference type="PDBsum" id="3PLF"/>
<dbReference type="PDBsum" id="4A49"/>
<dbReference type="PDBsum" id="4A4B"/>
<dbReference type="PDBsum" id="4A4C"/>
<dbReference type="PDBsum" id="4GPL"/>
<dbReference type="PDBsum" id="5HKW"/>
<dbReference type="PDBsum" id="5HKX"/>
<dbReference type="PDBsum" id="5HKY"/>
<dbReference type="PDBsum" id="5HKZ"/>
<dbReference type="PDBsum" id="5HL0"/>
<dbReference type="PDBsum" id="5J3X"/>
<dbReference type="PDBsum" id="5O76"/>
<dbReference type="ProteinModelPortal" id="P22681"/>
<dbReference type="SMR" id="P22681"/>
<dbReference type="BioGrid" id="107315">
<property type="interactions" value="250"/>
</dbReference>
<dbReference type="CORUM" id="P22681"/>
<dbReference type="DIP" id="DIP-189N"/>
<dbReference type="IntAct" id="P22681">
<property type="interactions" value="93"/>
</dbReference>
<dbReference type="MINT" id="MINT-109040"/>
<dbReference type="STRING" id="9606.ENSP00000264033"/>
<dbReference type="iPTMnet" id="P22681"/>
<dbReference type="PhosphoSitePlus" id="P22681"/>
<dbReference type="BioMuta" id="CBL"/>
<dbReference type="DMDM" id="251757253"/>
<dbReference type="EPD" id="P22681"/>
<dbReference type="MaxQB" id="P22681"/>
<dbReference type="PaxDb" id="P22681"/>
<dbReference type="PeptideAtlas" id="P22681"/>
<dbReference type="PRIDE" id="P22681"/>
<dbReference type="Ensembl" id="ENST00000264033">
<property type="protein sequence ID" value="ENSP00000264033"/>
<property type="gene ID" value="ENSG00000110395"/>
</dbReference>
<dbReference type="GeneID" id="867"/>
<dbReference type="KEGG" id="hsa:867"/>
<dbReference type="UCSC" id="uc001pwe.5">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="867"/>
<dbReference type="DisGeNET" id="867"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000110395.5"/>
<dbReference type="GeneCards" id="CBL"/>
<dbReference type="HGNC" id="HGNC:1541">
<property type="gene designation" value="CBL"/>
</dbReference>
<dbReference type="HPA" id="CAB004350"/>
<dbReference type="HPA" id="HPA027956"/>
<dbReference type="MalaCards" id="CBL"/>
<dbReference type="MIM" id="165360">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="613563">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P22681"/>
<dbReference type="OpenTargets" id="ENSG00000110395"/>
<dbReference type="Orphanet" id="86834">
<property type="disease" value="Juvenile myelomonocytic leukemia"/>
</dbReference>
<dbReference type="Orphanet" id="363972">
<property type="disease" value="Noonan syndrome-like disorder with juvenile myelomonocytic leukemia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA26115"/>
<dbReference type="eggNOG" id="KOG1785">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="ENOG410YDNH">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00390000011617"/>
<dbReference type="HOGENOM" id="HOG000294176"/>
<dbReference type="HOVERGEN" id="HBG005255"/>
<dbReference type="InParanoid" id="P22681"/>
<dbReference type="KO" id="K04707"/>
<dbReference type="OMA" id="CEHPKIK"/>
<dbReference type="OrthoDB" id="EOG091G0GPE"/>
<dbReference type="PhylomeDB" id="P22681"/>
<dbReference type="TreeFam" id="TF314210"/>
<dbReference type="BRENDA" id="2.3.2.B10">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1236382">
<property type="pathway name" value="Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1295596">
<property type="pathway name" value="Spry regulation of FGF signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1433559">
<property type="pathway name" value="Regulation of KIT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-182971">
<property type="pathway name" value="EGFR downregulation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2173789">
<property type="pathway name" value="TGF-beta receptor signaling activates SMADs"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5637810">
<property type="pathway name" value="Constitutive Signaling by EGFRvIII"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654726">
<property type="pathway name" value="Negative regulation of FGFR1 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654727">
<property type="pathway name" value="Negative regulation of FGFR2 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654732">
<property type="pathway name" value="Negative regulation of FGFR3 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654733">
<property type="pathway name" value="Negative regulation of FGFR4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6783589">
<property type="pathway name" value="Interleukin-6 family signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6807004">
<property type="pathway name" value="Negative regulation of MET activity"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8849469">
<property type="pathway name" value="PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8856825">
<property type="pathway name" value="Cargo recognition for clathrin-mediated endocytosis"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8856828">
<property type="pathway name" value="Clathrin-mediated endocytosis"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8875360">
<property type="pathway name" value="InlB-mediated entry of Listeria monocytogenes into host cell"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-912631">
<property type="pathway name" value="Regulation of signaling by CBL"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-983695">
<property type="pathway name" value="Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"/>
</dbReference>
<dbReference type="SignaLink" id="P22681"/>
<dbReference type="SIGNOR" id="P22681"/>
<dbReference type="UniPathway" id="UPA00143"/>
<dbReference type="ChiTaRS" id="CBL">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P22681"/>
<dbReference type="GeneWiki" id="CBL_(gene)"/>
<dbReference type="GenomeRNAi" id="867"/>
<dbReference type="PMAP-CutDB" id="P22681"/>
<dbReference type="PRO" id="PR:P22681"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 11"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000110395"/>
<dbReference type="CleanEx" id="HS_CBL"/>
<dbReference type="ExpressionAtlas" id="P22681">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P22681">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0030424">
<property type="term" value="C:axon"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0016600">
<property type="term" value="C:flotillin complex"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005925">
<property type="term" value="C:focal adhesion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030426">
<property type="term" value="C:growth cone"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042629">
<property type="term" value="C:mast cell granule"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="GOC"/>
</dbReference>
<dbReference type="GO" id="GO:0045121">
<property type="term" value="C:membrane raft"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0048471">
<property type="term" value="C:perinuclear region of cytoplasm"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0045296">
<property type="term" value="F:cadherin binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005509">
<property type="term" value="F:calcium ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0003700">
<property type="term" value="F:DNA binding transcription factor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0046875">
<property type="term" value="F:ephrin receptor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005154">
<property type="term" value="F:epidermal growth factor receptor binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0036312">
<property type="term" value="F:phosphatidylinositol 3-kinase regulatory subunit binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001784">
<property type="term" value="F:phosphotyrosine residue binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0030971">
<property type="term" value="F:receptor tyrosine kinase binding"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0017124">
<property type="term" value="F:SH3 domain binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0004871">
<property type="term" value="F:signal transducer activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0061630">
<property type="term" value="F:ubiquitin protein ligase activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0004842">
<property type="term" value="F:ubiquitin-protein transferase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0007166">
<property type="term" value="P:cell surface receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0006974">
<property type="term" value="P:cellular response to DNA damage stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0071364">
<property type="term" value="P:cellular response to epidermal growth factor stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1990090">
<property type="term" value="P:cellular response to nerve growth factor stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0090650">
<property type="term" value="P:cellular response to oxygen-glucose deprivation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0036120">
<property type="term" value="P:cellular response to platelet-derived growth factor stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035635">
<property type="term" value="P:entry of bacterium into host cell"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007173">
<property type="term" value="P:epidermal growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0008543">
<property type="term" value="P:fibroblast growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008584">
<property type="term" value="P:male gonad development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043303">
<property type="term" value="P:mast cell degranulation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0061024">
<property type="term" value="P:membrane organization"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042059">
<property type="term" value="P:negative regulation of epidermal growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007175">
<property type="term" value="P:negative regulation of epidermal growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:1901215">
<property type="term" value="P:negative regulation of neuron death"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0070997">
<property type="term" value="P:neuron death"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045742">
<property type="term" value="P:positive regulation of epidermal growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0014068">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048260">
<property type="term" value="P:positive regulation of receptor-mediated endocytosis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006513">
<property type="term" value="P:protein monoubiquitination"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000209">
<property type="term" value="P:protein polyubiquitination"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016567">
<property type="term" value="P:protein ubiquitination"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0042787">
<property type="term" value="P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014823">
<property type="term" value="P:response to activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0046677">
<property type="term" value="P:response to antibiotic"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045471">
<property type="term" value="P:response to ethanol"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010332">
<property type="term" value="P:response to gamma radiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042594">
<property type="term" value="P:response to starvation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0033574">
<property type="term" value="P:response to testosterone"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007179">
<property type="term" value="P:transforming growth factor beta receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="CDD" id="cd09920">
<property type="entry name" value="SH2_Cbl-b_TKB"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="1.20.930.20">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.30.40.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.30.505.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR024162">
<property type="entry name" value="Adaptor_Cbl"/>
</dbReference>
<dbReference type="InterPro" id="IPR014741">
<property type="entry name" value="Adaptor_Cbl_EF_hand-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR036537">
<property type="entry name" value="Adaptor_Cbl_N_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR003153">
<property type="entry name" value="Adaptor_Cbl_N_hlx"/>
</dbReference>
<dbReference type="InterPro" id="IPR014742">
<property type="entry name" value="Adaptor_Cbl_SH2-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR024159">
<property type="entry name" value="Cbl_PTB"/>
</dbReference>
<dbReference type="InterPro" id="IPR011992">
<property type="entry name" value="EF-hand-dom_pair"/>
</dbReference>
<dbReference type="InterPro" id="IPR036860">
<property type="entry name" value="SH2_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR015940">
<property type="entry name" value="UBA"/>
</dbReference>
<dbReference type="InterPro" id="IPR009060">
<property type="entry name" value="UBA-like_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR001841">
<property type="entry name" value="Znf_RING"/>
</dbReference>
<dbReference type="InterPro" id="IPR013083">
<property type="entry name" value="Znf_RING/FYVE/PHD"/>
</dbReference>
<dbReference type="InterPro" id="IPR017907">
<property type="entry name" value="Znf_RING_CS"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR23007">
<property type="entry name" value="PTHR23007"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF02262">
<property type="entry name" value="Cbl_N"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF02761">
<property type="entry name" value="Cbl_N2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF02762">
<property type="entry name" value="Cbl_N3"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00627">
<property type="entry name" value="UBA"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00184">
<property type="entry name" value="RING"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00165">
<property type="entry name" value="UBA"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF46934">
<property type="entry name" value="SSF46934"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF47473">
<property type="entry name" value="SSF47473"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF47668">
<property type="entry name" value="SSF47668"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF55550">
<property type="entry name" value="SSF55550"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51506">
<property type="entry name" value="CBL_PTB"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50030">
<property type="entry name" value="UBA"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00518">
<property type="entry name" value="ZF_RING_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50089">
<property type="entry name" value="ZF_RING_2"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0106">Calcium</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0656">Proto-oncogene</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0833">Ubl conjugation pathway</keyword>
<keyword id="KW-0862">Zinc</keyword>
<keyword id="KW-0863">Zinc-finger</keyword>
<feature type="chain" description="E3 ubiquitin-protein ligase CBL" id="PRO_0000055858">
<location>
<begin position="1"/>
<end position="906"/>
</location>
</feature>
<feature type="domain" description="Cbl-PTB" evidence="18">
<location>
<begin position="47"/>
<end position="351"/>
</location>
</feature>
<feature type="domain" description="UBA" evidence="17">
<location>
<begin position="856"/>
<end position="895"/>
</location>
</feature>
<feature type="calcium-binding region">
<location>
<begin position="227"/>
<end position="240"/>
</location>
</feature>
<feature type="zinc finger region" description="RING-type" evidence="16">
<location>
<begin position="381"/>
<end position="420"/>
</location>
</feature>
<feature type="region of interest" description="Sufficient for interaction with EPHB1" evidence="41">
<location>
<begin position="1"/>
<end position="357"/>
</location>
</feature>
<feature type="region of interest" description="4H">
<location>
<begin position="47"/>
<end position="175"/>
</location>
</feature>
<feature type="region of interest" description="EF-hand-like">
<location>
<begin position="176"/>
<end position="248"/>
</location>
</feature>
<feature type="region of interest" description="SH2-like">
<location>
<begin position="249"/>
<end position="351"/>
</location>
</feature>
<feature type="region of interest" description="Linker">
<location>
<begin position="352"/>
<end position="380"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with CD2AP" evidence="25">
<location>
<begin position="648"/>
<end position="906"/>
</location>
</feature>
<feature type="compositionally biased region" description="Asp/Glu-rich (acidic)">
<location>
<begin position="357"/>
<end position="476"/>
</location>
</feature>
<feature type="compositionally biased region" description="Pro-rich">
<location>
<begin position="477"/>
<end position="688"/>
</location>
</feature>
<feature type="compositionally biased region" description="Asp/Glu-rich (acidic)">
<location>
<begin position="689"/>
<end position="834"/>
</location>
</feature>
<feature type="binding site" description="Phosphotyrosine" evidence="14">
<location>
<position position="294"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by INSR" evidence="29">
<location>
<position position="371"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="439"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12">
<location>
<position position="452"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="483"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="15">
<location>
<position position="619"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="15">
<location>
<position position="642"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="15">
<location>
<position position="668"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="669"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="49">
<location>
<position position="674"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by ABL1" evidence="29 37 49">
<location>
<position position="700"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by SRC" evidence="34">
<location>
<position position="731"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="29 49">
<location>
<position position="774"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11">
<location>
<position position="900"/>
</location>
</feature>
<feature type="sequence variant" description="Found in patients with acute myeloid leukemia; unknown pathological significance." id="VAR_071040" evidence="49">
<original>K</original>
<variation>R</variation>
<location>
<position position="287"/>
</location>
</feature>
<feature type="sequence variant" description="Found in patients with acute myeloid leukemia; unknown pathological significance; loss of the ability to negatively regulate signaling pathways; promotes cell cycle progression; decreases apoptosis." id="VAR_071041">
<original>Q</original>
<variation>QSK</variation>
<location>
<position position="365"/>
</location>
</feature>
<feature type="sequence variant" description="In NSLL; dbSNP:rs267606704." id="VAR_064332" evidence="48">
<original>Q</original>
<variation>P</variation>
<location>
<position position="367"/>
</location>
</feature>
<feature type="sequence variant" description="Found in patients with acute myeloid leukemia; unknown pathological significance; loss of the ability to negatively regulate signaling pathways; promotes cell cycle progression; decreases apoptosis; dbSNP:rs267606706." id="VAR_071042" evidence="49">
<original>Y</original>
<variation>H</variation>
<location>
<position position="371"/>
</location>
</feature>
<feature type="sequence variant" description="In NSLL; dominant-negative; impairs CBL-mediated ubiquitination, internalization and degradation of the EGF receptor/EGFR; decreases the ability to negatively regulate EGFR signaling; dbSNP:rs267606705." id="VAR_064333" evidence="51">
<original>K</original>
<variation>E</variation>
<location>
<position position="382"/>
</location>
</feature>
<feature type="sequence variant" description="In NSLL; dominant-negative; impairs CBL-mediated ubiquitination, internalization and degradation of the EGF receptor/EGFR; decreases the ability to negatively regulate EGFR signaling; dbSNP:rs267606707." id="VAR_064334" evidence="48 51">
<original>D</original>
<variation>Y</variation>
<location>
<position position="390"/>
</location>
</feature>
<feature type="sequence variant" description="In NSLL; dominant-negative; impairs CBL-mediated ubiquitination, internalization and degradation of the EGF receptor/EGFR; decreases the ability to negatively regulate EGFR signaling; dbSNP:rs267606708." id="VAR_064335" evidence="48 51">
<original>R</original>
<variation>Q</variation>
<location>
<position position="420"/>
</location>
</feature>
<feature type="sequence variant" description="Found in patients with acute myeloid leukemia; unknown pathological significance." id="VAR_071043" evidence="49">
<original>R</original>
<variation>L</variation>
<location>
<position position="499"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2227988." id="VAR_057211">
<original>L</original>
<variation>F</variation>
<location>
<position position="620"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2229073." id="VAR_057212">
<original>P</original>
<variation>L</variation>
<location>
<position position="782"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs17122769." id="VAR_057213">
<original>V</original>
<variation>I</variation>
<location>
<position position="904"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70." evidence="19">
<original>S</original>
<variation>D</variation>
<location>
<position position="80"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70." evidence="19">
<original>P</original>
<variation>A</variation>
<location>
<position position="82"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70." evidence="19">
<original>D</original>
<variation>Q</variation>
<location>
<position position="229"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70." evidence="19">
<original>E</original>
<variation>S</variation>
<location>
<position position="240"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70." evidence="19">
<original>R</original>
<variation>K</variation>
<location>
<position position="294"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with ZAP70 and EPHB1, but does not affect interaction with SLA." evidence="19 22">
<original>G</original>
<variation>E</variation>
<location>
<position position="306"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduces tyrosine phosphorylation by INSR; when associated with F-700 and F-774." evidence="29">
<original>Y</original>
<variation>F</variation>
<location>
<position position="371"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of ubiquitin ligase activity." evidence="28">
<original>C</original>
<variation>A</variation>
<location>
<position position="381"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduces tyrosine phosphorylation by INSR; when associated with F-371 and F-774." evidence="29">
<original>Y</original>
<variation>F</variation>
<location>
<position position="700"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on tyrosine phosphorylation by INSR. Loss of phosphorylation by SRC. Inhibition of bone resorption. Abolishes interaction with PIK3R1." evidence="29 34">
<original>Y</original>
<variation>F</variation>
<location>
<position position="731"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduces tyrosine phosphorylation by INSR; when associated with F-371 and F-700." evidence="29">
<original>Y</original>
<variation>F</variation>
<location>
<position position="774"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA40393." ref="1" evidence="57">
<original>S</original>
<variation>T</variation>
<location>
<position position="15"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="53"/>
<end position="70"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="73"/>
<end position="75"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="80"/>
<end position="82"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="84"/>
<end position="101"/>
</location>
</feature>
<feature type="turn" evidence="10">
<location>
<begin position="102"/>
<end position="104"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="106"/>
<end position="111"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="113"/>
<end position="136"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="137"/>
<end position="141"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="146"/>
<end position="168"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="170"/>
<end position="172"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="176"/>
<end position="178"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="184"/>
<end position="194"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="198"/>
<end position="201"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="202"/>
<end position="212"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="218"/>
<end position="228"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="233"/>
<end position="237"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="238"/>
<end position="247"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="251"/>
<end position="253"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="254"/>
<end position="261"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="262"/>
<end position="264"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="268"/>
<end position="271"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="274"/>
<end position="281"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="282"/>
<end position="284"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="290"/>
<end position="295"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="297"/>
<end position="299"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="302"/>
<end position="308"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="310"/>
<end position="312"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="314"/>
<end position="317"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="320"/>
<end position="322"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="324"/>
<end position="333"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="350"/>
<end position="352"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="354"/>
<end position="356"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="360"/>
<end position="362"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="365"/>
<end position="378"/>
</location>
</feature>
<feature type="turn" evidence="9">
<location>
<begin position="382"/>
<end position="384"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="385"/>
<end position="388"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="391"/>
<end position="394"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="398"/>
<end position="400"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="402"/>
<end position="410"/>
</location>
</feature>
<feature type="turn" evidence="9">
<location>
<begin position="417"/>
<end position="419"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="425"/>
<end position="428"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="430"/>
<end position="432"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="856"/>
<end position="866"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="871"/>
<end position="880"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="881"/>
<end position="883"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="885"/>
<end position="895"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1FBV"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2K4D"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2OO9"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2Y1M"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BUO"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BUW"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BUX"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4A49"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5HKX"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5HKY"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="16964243"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="19690332"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000250"/>
<evidence key="15" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P22682"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00175"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00212"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00839"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10078535"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10092522"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10374881"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10449770"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10514377"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10966114"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11067845"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11696592"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11850825"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11896602"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11997497"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12435267"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12486104"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12504111"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14661060"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14739300"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15190072"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15226403"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15556646"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15958209"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17509076"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17620338"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18034775"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18235045"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18374639"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19689429"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19836242"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20094046"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20494825"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20619386"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20622007"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21596750"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25178484"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7657591"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8083187"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9407100"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9535867"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9989826"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000305"/>
<sequence length="906" mass="99633" checksum="1AA6BF67377322CA" modified="2009-07-07" version="2">
MAGNVKKSSGAGGGSGSGGSGSGGLIGLMKDAFQPHHHHHHHLSPHPPGTVDKKMVEKCW
KLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFME
NLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFR
ITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFE
FDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRL
GQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTGLCEPTPQDH
IKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQESEGQGCPFCR
CEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDTLFMMKELAGAKVER
PPSPFSMAPQASLPPVPPRLDLLPQRVCVPSSASALGTASKAASGSLHKDKPLPVPPTLR
DLPPPPPPDRPYSVGAESRPQRRPLPCTPGDCPSRDKLPPVPSSRLGDSWLPRPIPKVPV
SAPSSSDPWTGRELTNRHSLPFSLPSQMEPRPDVPRLGSTFSLDTSMSMNSSPLVGPECD
HPKIKPSSSANAIYSLAARPLPVPKLPPGEQCEGEEDTEYMTPSSRPLRPLDTSQSSRAC
DCDQQIDSCTYEAMYNIQSQAPSITESSTFGEGNLAAAHANTGPEESENEDDGYDVPKPP
VPAVLARRTLSDISNASSSFGWLSLDGDPTTNVTEGSQVPERPPKPFPRRINSERKAGSC
QQGSGPAASAATASPQLSSEIENLMSQGYSYQDIQKALVIAQNNIEMAKNILREFVSISS
PAHVAT
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>